Screening for prostate cancer

There is no national screening programme for prostate cancer in the UK. This is because there isn’t a reliable test that can pick up prostate cancer that needs treatment at an early stage.

Overall research has shown that current tests don’t reduce the number of men dying from prostate cancer. Research is going on to find a new test. Or see if the current test is more effective if used in a different way and can find the cancers that need treatment more accurately.

What is cancer screening?

Screening means testing people for early stages of a cancer, or for early changes that could develop into cancer if left untreated. For screening to be useful the tests:

  • need to be reliable at picking up cancers that need treatment
  • overall must do more good than harm to people taking part
  • must be something that people are willing to do

Screening tests are not perfect and have some risks. The screening programme should also be good value for money for the NHS.

Why there isn’t a screening programme for prostate cancer in the UK

The UK National Screening Committee doesn’t currently recommend screening for prostate cancer. This is because the PSA test is not reliable enough to detect prostate cancer that needs treatment.

What is the PSA test?

PSA stands for prostate specific antigen. It’s a protein made by both normal and cancerous prostate cells. It's normal for all men to have some PSA in their blood.

A high level of PSA can be a sign of prostate cancer. But your PSA level can also be raised because of other conditions that aren't cancer. This includes:

  • a urine infection
  • a benign enlarged prostate

The PSA test can also miss some prostate cancers. Research has shown that 1 in 7 men with a normal PSA level have prostate cancer. And that 1 in 50 men with a normal PSA level have a fast growing prostate cancer.

Because of this, the PSA test on its own is not recommended as a screening test for prostate cancer. But men over 50 can usually ask their GP for a PSA blood test if they want. Your GP will explain the potential benefits and risks of having a PSA test.  

Understanding your PSA test results

PSA is usually measured in nanograms per millilitre of blood (ng/mL). There is no one PSA value that is considered normal. The value varies from man to man and increases as you get older. Most men have a PSA level of less than 3ng/ml. 

Your GP or specialist may suggest further tests if your PSA level is higher than would be expected for someone of your age. Talk to your doctor about your PSA level and what this means for you.

Research into prostate cancer screening

Research is ongoing to find other prostate cancer screening tests and ways to improve the current test. This includes:

  • new blood and urine tests
  • a combination of a blood test and other information such as age and family history
  • MRI and other types of scans

More research is needed to find out whether these tests are reliable enough to detect prostate cancer.

What to do if you think you are at higher risk of prostate cancer

Speak to your GP if you think you are at higher risk of prostate cancer. For example if you:

  • are a Black male or a Black person who has a prostate
  • have a close relative, such as brother or father, who has prostate cancer
  • have inherited certain genes which can increase the risk of prostate cancer

The risk of prostate cancer also increases as men get older.

The evidence so far suggests that routinely screening people who have a high risk of prostate cancer doesn’t help prevent deaths. In fact, it might lead to men having treatment for prostate cancer even though that cancer wouldn’t have caused any problems or symptoms.

What to do if you are worried about prostate cancer

Talk to your GP if you're worried about prostate cancer. Or if you have urinary symptoms such as difficulty passing urine. The symptoms don't mean that you have prostate cancer, but it is important to get them checked.  

  • Adult screening programme – Prostate cancer
    UK National Screening Committee, Last accessed March 20222

  • Screening for prostate cancer. External review against programme appraisal criteria for the UK National Screening Committee
    UK National Screening Committee, October 2020

  • Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow up
    C Parker and others
    Annals of Oncology, 2020. Vol 31, Issue 9. Pages 1119-1134

  • Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis
    D W Bruner and others
    International Journal of cancer, 2003. Vol 107, Issue 5. Pages 797-803

  • Cancer Risks Associated with BRCA1 and BRCA2 pathogenic variants
    Li Shuai and others
    Journal of Clinical Oncology, 2022 (published online). Last accessed March 2022

  • The information on this page is based on literature searches and specialist checking. We used many references and there are too many to list here. Please contact patientinformation@cancer.org.uk with details of the particular issue you are interested in if you need additional references for this information.

Last reviewed: 
26 Apr 2022
Next review due: 
26 Apr 2025

Related links